Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Moderate Buy” from Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has earned a consensus rating of “Moderate Buy” from the eighteen ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, sixteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $289.8824.

ASND has been the topic of a number of research reports. Evercore restated an “outperform” rating and set a $324.00 price target on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. TD Cowen reissued a “buy” rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 7th. Wedbush upped their price target on shares of Ascendis Pharma A/S from $240.00 to $273.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Royal Bank Of Canada increased their price objective on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a research report on Monday, March 2nd. Finally, Bank of America reissued a “buy” rating and issued a $262.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently made changes to their positions in the business. Advisory Services Network LLC bought a new position in Ascendis Pharma A/S in the third quarter worth approximately $26,000. Arax Advisory Partners boosted its position in Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 104 shares in the last quarter. Leonteq Securities AG purchased a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at $36,000. First Horizon Advisors Inc. bought a new position in shares of Ascendis Pharma A/S in the 2nd quarter worth $41,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Ascendis Pharma A/S in the 4th quarter worth $42,000.

Ascendis Pharma A/S Stock Down 0.3%

Shares of Ascendis Pharma A/S stock opened at $239.92 on Tuesday. Ascendis Pharma A/S has a twelve month low of $124.06 and a twelve month high of $248.60. The company has a market cap of $14.87 billion, a price-to-earnings ratio of -54.53 and a beta of 0.43. The company’s 50 day moving average is $222.76 and its 200 day moving average is $210.28.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 11th. The biotechnology company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The business had revenue of $290.38 million for the quarter, compared to analyst estimates of $285.35 million. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.